Anti-CCP Prognostic Value — SCE Rheumatology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Anti-CCP positivity predicts greater radiographic progression; it supports a remission target but alone does not dictate a specific DMARD regimen.
Anti-CCP positivity is an established adverse prognostic marker for structural joint damage. NICE advises patients with anti-CCP antibodies that they have an increased risk of radiological progression, although this does not necessarily predict poor functional outcome. NICE also recommends considering remission, rather than low disease activity, as the treatment target in this group. RF is also prognostic, so A is incorrect. Anti-CCP is not solely diagnostic, excluding B, and low titres are not known to confer greater risk than high titres, excluding D. Anti-CCP concentrations are not validated serial disease-activity measures and should not independently determine DMARD escalation, excluding E. Treatment remains treat-to-target, based primarily on clinical disease activity, response and toxicity.
Reference: National Institute for Health and Care Excellence. Rheumatoid arthritis in adults: management (NG100), recommendations 1.1.6 and 1.2.2. 2018; reviewed 2024. https://www.nice.org.uk/guidance/ng100/chapter/Recommendations